Within Subject, Dose-Escalation Trial of Continuously Infused Intraputamental (Ipu) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Subjects with Idiopathic Parkinson's Disease